# US 8,772,344 B2 · Pharmaceutical composition for inhibiting osteoclast growth

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,772,344 B2
- Document ID: US8772344B2
- Status: Granted
- Kind: B2
- Application number: 13/180,253
- Filed: 2011-07-11
- Published: 2012-09-13
- Granted: 2014-07-08
- Earliest claimed: 2011-03-11
- Assignees: National Defense Medical Center
- Applicants: Deh-Ming Chang; Hsu-Shan Huang
- Inventors: Deh-Ming Chang; Hsu-Shan Huang
- Web page: https://patentgrep.com/patent/US8772344B2

## CPC

- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 31/426: 1,3-Thiazoles
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical composition for inhibiting osteoclast growth is disclosed in the present invention. The pharmaceutical composition includes a compound represented by a formula (I), and a pharmaceutically acceptable salt and carrier: wherein R1, R2, R3, R4 can be one selected from a group consisting of hydrogen, halogen, C1˜C10 alkyl group, C2˜C10 alkynyl group, amino group, haloalkyl group and sulfonamide group.

## Claims

### Claim 1

A pharmaceutical composition for inhibiting osteoclast precursor growth comprising N-(3-ethynylphenyl)-2-hydroxybenzamide, a pharmaceutically acceptable salt, and a carrier.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the carrier is an excipient, a diluent, a thickener, a filler, a binder, a disintegrant, a lubricant, a oleaginous base, an non-oleaginous base, a surfactant, a suspending agent, a coagulant, an auxiliary agent, a preservative, an anti-oxidant, a stabilizer, a colorant or a flavoring.

### Claim 3 (depends on 2)

The pharmaceutical composition according to claim 2, wherein the excipient comprises microcrystalline cellulose, polyvinylpyrrolidone, corn starch, modified starches, sodium starch glycolate, resin, gelatinized starches, carbohydrate, polyethylene glycol, polyvinyl alcohol, hydroxypropyl cellulose, methylcellulose, hydroxymethyl cellulose or hydroxypropyl methylcellulose.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutically acceptable salt is a physiologically acceptable with inorganic/organic acid or base.

### Claim 5 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is a powder, a grain, a liquid, a colloid or a paste.

### Claim 6 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is formulated for oral administration, transcutaneous administration, injection administration or inhalation administration.